These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 1434911)

  • 21. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
    Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
    Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
    Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms underlying the laxative effect of lactulose: A randomized placebo-controlled trial showing increased small bowel water and motility unaltered by the 5-HT
    Gunn D; Yeldho C; Hoad C; Menys A; Gowland P; Marciani L; Spiller R
    Neurogastroenterol Motil; 2024 Apr; 36(4):e14754. PubMed ID: 38316636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of Ondansetron on Improvement of Symptoms in Patients with Irritable Bowel Syndrome with Diarrhea Domination: A Randomized Controlled Trial.
    Jafari S; Atmani A; Gohari S; Seifi E
    Middle East J Dig Dis; 2024 Jul; 16(3):178-184. PubMed ID: 39386337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome.
    Gorard DA; Libby GW; Farthing MJ
    Aliment Pharmacol Ther; 1994 Apr; 8(2):159-66. PubMed ID: 8038347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.
    Odunsi-Shiyanbade ST; Camilleri M; McKinzie S; Burton D; Carlson P; Busciglio IA; Lamsam J; Singh R; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2010 Feb; 8(2):159-65. PubMed ID: 19879973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome.
    Hammer J; Phillips SF; Talley NJ; Camilleri M
    Aliment Pharmacol Ther; 1993 Oct; 7(5):543-51. PubMed ID: 8280823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Kim DY; McKinzie S; Kim HJ; Thomforde GM; Burton DD; Low PA; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):111-21. PubMed ID: 15017503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.
    Rao AS; Wong BS; Camilleri M; Odunsi-Shiyanbade ST; McKinzie S; Ryks M; Burton D; Carlson P; Lamsam J; Singh R; Zinsmeister AR
    Gastroenterology; 2010 Nov; 139(5):1549-58, 1558.e1. PubMed ID: 20691689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
    Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of irritable bowel syndrome with a novel colonic irrigation system: a pilot study.
    Hsu HH; Leung WH; Hu GC
    Tech Coloproctol; 2016 Aug; 20(8):551-7. PubMed ID: 27194235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.
    Wong BS; Camilleri M; Eckert D; Carlson P; Ryks M; Burton D; Zinsmeister AR
    Neurogastroenterol Motil; 2012 Apr; 24(4):358-e169. PubMed ID: 22288893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
    Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study.
    Bearcroft CP; Perrett D; Farthing MJ
    Gut; 1998 Jan; 42(1):42-6. PubMed ID: 9505884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity.
    Gonlachanvit S; Mahayosnond A; Kullavanijaya P
    Neurogastroenterol Motil; 2009 Jan; 21(1):23-32. PubMed ID: 18647268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.
    Gunn D; Topan R; Barnard L; Fried R; Holloway I; Brindle R; Corsetti M; Scott M; Farmer A; Kapur K; Sanders D; Eugenicos M; Trudgill N; Whorwell P; Mclaughlin J; Akbar A; Houghton L; Dinning PG; Aziz Q; Ford AC; Farrin AJ; Spiller R
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1258-1271. PubMed ID: 36866724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin.
    Shekhar C; Monaghan PJ; Morris J; Issa B; Whorwell PJ; Keevil B; Houghton LA
    Gastroenterology; 2013 Oct; 145(4):749-57; quiz e13-4. PubMed ID: 23872499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.